Caroline Baumal

CIK 1961100 · Chief Medical Officer · last filed 2026-05-14

Caroline Baumal is a Chief Medical Officer who has filed 11 SEC Form 4 insider transactions across 1 company since 2023. The most recent filing, for APLS, was dated May 14, 2026. Across all open-market trades the lifetime net is −$491.2K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

11

Lifetime Open-Market Net

-$491.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Apellis Pharmaceuticals, Inc. (APLS) Delisted Chief Medical Officer 0 $41.03 $0 -$491.2K 11 2026-05-14

Recent Filings

11 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-05-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −137,832 $0 EDGAR
2026-05-01 Apellis Pharmaceuticals, Inc. (APLS) Delisted Gift (G) −900 $0 EDGAR
2026-01-23 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −2,797 -$60.9K EDGAR
2026-01-21 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −1,882 -$37.3K EDGAR
2026-01-06 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −3,020 -$77.1K EDGAR
2025-06-11 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) $0 EDGAR
2025-01-21 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed +37,741 -$55.5K EDGAR
2025-01-08 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −2,816 -$95.2K EDGAR
2024-01-17 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +25,445 $0 EDGAR
2024-01-05 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −2,751 -$165.2K EDGAR
Showing 110 of 11
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.